Histofy, a leader in the development of transparent AI solutions for pathology, proudly announces the formation of its Scientific Advisory Board. This milestone reflects Histofy’s commitment to integrating world-class expertise into its innovative product line, ensuring real-world impact.
Coventry, UK (22nd July 2024) – Histofy is pleased to introduce its new Scientific Advisory Board, comprising five esteemed leaders across pathology and oncology. The Board shall meet regularly with the Histofy core team, to offer guidance and feedback, and to identify emerging needs within the pathology sector.
Advisory Board Composition
The board members are:
- Professor Mark Arends – Professor of Pathology, Head of Pathology, and Co-director of the Centre for Comparative Pathology at the University of Edinburgh.
- Professor Ali Khurram – Professor and Honorary Consultant in Oral and Maxillofacial Pathology at the University of Sheffield, and Founder and Lead of the NeoPATH Research Group.
- Dr Sabine Tejpar – Associate Professor in the Faculty of Medicine, Head of Digestive Oncology, and Head of the Subdivision of Molecular Genetics of Colorectal Tumours at KU Leuven.
- Dr Jonathan Williams – Head of Pathology and Senior Lecturer in Veterinary Anatomic Pathology at the Royal Veterinary College. Fellow of the Higher Education Academy (FHEA), Diplomate of the European College of Veterinary Pathologists (ECVP), and a Royal College of Veterinary Surgeons (RCVS) member.
"I am delighted at the prospect of discussing real-world problems with our newly formed Scientific Advisory Board"
Nasir Rajpoot, CEO & CSO of Histofy, expressed his enthusiasm, saying, “I am delighted at the prospect of discussing real-world problems with our newly formed Scientific Advisory Board. Their feedback will be invaluable in shaping our future.”
Sabine Tejpar added, “I am excited to join Histofy’s Scientific Advisory Board because the integration of AI in pathology holds immense potential for improving diagnostic accuracy and efficiency. I look forward to contributing to the development of cutting-edge solutions that can transform patient care.”
Mark Arends remarked, “Joining Histofy’s Scientific Advisory Board is a great opportunity to apply advanced AI techniques to real-world pathology challenges. I am keen to collaborate with the team as the integration of AI in pathology holds great promise for streamlining pathology practice, ultimately improving the accuracy of diagnoses and therefore, making a huge difference to the outcome.”
Ali Khurram stated, “I am eager to collaborate with the team to push the frontiers of what AI can achieve in medical diagnostics. Being a part of Histofy’s Scientific Advisory Board is a unique opportunity to apply advanced techniques to help tackle challenges within pathology.”
About Histofy
Histofy develops transparent AI solutions for computational pathology to improve the treatment of various diseases, such as cancer. With a focus on tissue-based diagnostics and prognostics, our technology complements pathologists to help deliver better patient care. With leading research spanning over two decades, our team thoroughly understands the process of technology development, from concept to validation, placing us in prime position to bring cutting-edge AI to clinical and pharmaceutical settings.
